Oral thrombostatin FM19 inhibits prostate cancer

Thrombosis and Haemostasis

Volumn 104, Issue 5, 2010, Pages 1044-1048

  Nieman, Marvin T ^a   LaRusch, Gretchen A ^a   Fang, Chao ^a   Zhou, Yihua ^a   Schmaier, Alvin H ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Cancer treatment; Oral direct thrombin inhibitor; Prostate cancer

Indexed keywords

FM 19; HIRULOG; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING TENDENCY; CALCIUM MOBILIZATION; CANCER CELL; CANCER INVASION; CANCER THERAPY; CELL DIVISION; CELL PROLIFERATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; IC 50; IN VIVO CULTURE; MALE; METASTASIS; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; THROMBIN TIME; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTITHROMBINS; BLOOD COAGULATION; BRADYKININ; CALCIUM SIGNALING; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; THROMBIN; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78149481975     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-08-0570     Document Type: Article

References (25)

1. Sanders RJ, Mainiero F, Giancotti FG. The role of integrins in tumorigenesis and metastasis. Cancer Invest 1998; 16: 329-344.
2. Schnitzer JE. Vascular targeting as a strategy for cancer therapy. N Engl J Med 1998; 339: 472-474.
3. Hu L, Ibrahim S, Liu C, et al. Thrombin induces tumor cell cycle activation and spontaneous growth by down-regulation of p27Kip1, in association with the up-regulation of Skp2 and MiR-222. Cancer Res 2009; 69: 3374-3381.
4. Hu L, Lee M, Campbell W, et al. Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis. Blood 2004; 104: 2746-2751.
5. Chay CH, Cooper CR, Gendernalik JD, et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002; 60: 760-765.
6. Tantivejkul K, Loberg RD, Mawocha SC, et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005; 96: 641-652.
7. Liu J, Bastian M, Kohlschein P, et al. Expression of functional protease-activated receptor 1 in human prostate cancer cell lines. Urol Res 2003; 31: 163-168.
8. Yuan TC, Lin MF. Protease-activated receptor 1: a role in prostate cancer metastasis. Clin Prostate Cancer 2004; 3: 189-191.
9. Kaushal V, Kohli M, Dennis RA, et al. Thrombin receptor expression is upregulated in prostate cancer. Prostate 2006; 66: 273-282.
10. Yin YJ, Salah Z, Maoz M, et al. Oncogenic transformation induces tumor angiogenesis: a role for PAR1 activation. FASEB J 2003; 17: 163-174.
11. Yin YJ, Salah Z, Grisaru-Granovsky S, et al. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 2003; 23: 940-944.
12. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer 1993; 54: 793-806.
13. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998; 92: 3694-3700.
14. Kamath L, Meydani A, Foss F, et al. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001; 61: 5933-5940.
15. Shi X, Gangadharan B, Brass LF, et al. Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004; 2: 395-402.
16. Salah Z, Maoz M, Cohen I, et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J 2005; 19: 62-72.
17. Salah Z, Maoz M, Pizov G, et al. Transcriptional regulation of human protease-activated receptor 1: a role for the early growth response-1 protein in prostate cancer. Cancer Res 2007; 67: 9835-9843.
18. Hasan AA, Warnock M, Nieman M, et al. Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. Am J Physiol Heart Circ Physiol 2003; 285: H183-H193.
19. Nieman MT, Warnock M, Hasan AA, et al. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease- activated receptor 1. J Pharmacol Exp Ther 2004; 311: 492-501.
20. Burke FM, Warnock M, Schmaier AH, et al. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation. Chem Biol Drug Des 2006; 68: 235-238.
21. Nieman MT, Burke F, Warnock M, et al. Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. J Thromb Haemost 2008; 6: 837-845.
22. Schneider A, Kalikin LM, Mattos AC, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146: 1727-1736.
23. Johnson ML, Faunt LM. Parameter estimation by least-squares methods. Methods Enzymol 1992; 210: 1-37.
24. Beechem JM. Global analysis of biochemical and biophysical data. Methods Enzymol 1992; 210: 37-54.
25. Yuasa H, Amidon GL, Fleisher D. peptide carrier-mediate transport in interstinal brush border membrane vesicles of rats and rabbits: cephradine uptake and inhibition. Pharm Res. 1993; 10: 400-404.